NCT02820233 Studies of Neuregulin/ERBB Signaling in Human Heart
| NCT ID | NCT02820233 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Douglas B. Sawyer |
| Condition | Heart Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2015-06 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2015-06 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of severe coronary artery disease scheduled to undergo coronary artery bypass surgery. Exclusion Criteria: * less than 18 years of age * unwilling or unable to provide informed consent * known active myocarditis * hypertrophic cardiomyopathy * constrictive pericarditis or other significant pericardial disease * severe pulmonary hypertension * significant renal impairment (Cr \> 2.5 mg/dL) * severe ventricular arrhythmias * pregnancy
Contact & Investigator
Joanne Burgess, RN
✉ burgejs@mmc.orgFrequently Asked Questions
Who can join the NCT02820233 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02820233 currently recruiting?
Yes, NCT02820233 is actively recruiting participants. Contact the research team at burgejs@mmc.org for enrollment information.
Where is the NCT02820233 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT02820233 clinical trial?
NCT02820233 is sponsored by Douglas B. Sawyer. The trial plans to enroll 80 participants.